BioNTech (NASDAQ:BNTX) PT Set at $150.00 by Wells Fargo & Company

BioNTech (NASDAQ:BNTX) has been assigned a $150.00 price objective by equities researchers at Wells Fargo & Company in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price indicates a potential upside of 34.77% from the company’s current price.

A number of other brokerages have also recently issued reports on BNTX. Citigroup restated a “buy” rating and set a $140.00 price objective (down previously from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Truist Financial restated a “buy” rating and set a $155.00 price objective (up previously from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. Morgan Stanley boosted their price objective on shares of BioNTech from $132.00 to $133.00 and gave the company an “overweight” rating in a report on Thursday, July 10th. Wall Street Zen upgraded shares of BioNTech from a “sell” rating to a “hold” rating in a report on Saturday, June 7th. Finally, Leerink Partners set a $112.00 price objective on shares of BioNTech in a report on Monday, June 2nd. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and an average target price of $135.91.

BioNTech Stock Up 0.2%

Shares of NASDAQ:BNTX opened at $111.30 on Tuesday. BioNTech has a one year low of $78.39 and a one year high of $131.49. The company has a 50 day moving average of $108.86 and a 200-day moving average of $106.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 10.02. The stock has a market cap of $26.76 billion, a price-to-earnings ratio of -69.56 and a beta of 1.23.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, August 4th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%. The business had revenue of $306.46 million for the quarter, compared to analyst estimates of $161.26 million. During the same quarter in the prior year, the firm earned ($3.36) EPS. The firm’s quarterly revenue was up 102.6% compared to the same quarter last year. On average, sell-side analysts forecast that BioNTech will post -3.88 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

Institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC grew its stake in shares of BioNTech by 22.2% in the fourth quarter. FMR LLC now owns 7,701,476 shares of the company’s stock valued at $877,583,000 after acquiring an additional 1,401,547 shares in the last quarter. Capital International Investors grew its stake in shares of BioNTech by 38.6% in the fourth quarter. Capital International Investors now owns 1,415,566 shares of the company’s stock valued at $161,304,000 after acquiring an additional 394,434 shares in the last quarter. BNP Paribas Financial Markets lifted its position in BioNTech by 94.6% during the first quarter. BNP Paribas Financial Markets now owns 1,195,470 shares of the company’s stock worth $108,859,000 after purchasing an additional 581,173 shares during the period. Bank of New York Mellon Corp lifted its position in BioNTech by 58.8% during the second quarter. Bank of New York Mellon Corp now owns 1,108,719 shares of the company’s stock worth $118,045,000 after purchasing an additional 410,351 shares during the period. Finally, Aberdeen Group plc lifted its holdings in shares of BioNTech by 87.2% in the second quarter. Aberdeen Group plc now owns 721,928 shares of the company’s stock worth $76,864,000 after acquiring an additional 336,260 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.